AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24142869 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) 200, 400, and 600 mg daily oral dose
Number of subjects: 17
Study 24142869 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 17
Study 23014669 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1795
Study 19773681 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stop service for antenatal syphilis screening
Number of subjects: 3850
Study 19773681 — intervention group
Group type: COMPARATOR
Intervention: Conventional antenatal screening service
Number of subjects: 3850
Study 17679493 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation/Dialogue
Number of subjects: 0
Study 17679493 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation/No Dialogue
Number of subjects: 0
Study 17679493 — intervention group
Group type: COMPARATOR
Intervention: No Observation/Dialogue
Number of subjects: 0
Study 17679493 — intervention group
Group type: COMPARATOR
Intervention: No Observation/No Dialogue
Number of subjects: 0
Study 15283929 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy germ isoflavones (60 mg per day, capsules)
Number of subjects: 50
Study 15283929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11352236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with step‐down prednisolone, methotrexate, and sulfasalazine
Number of subjects: 155
Study 11352236 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine alone
Number of subjects: 155
Study 9388790 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus cue enhancement using mammography chart stickers
Number of subjects: 11716
Study 9388790 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus cue enhancement plus feedback and token rewards
Number of subjects: 11716
Study 9388790 — intervention group
Group type: COMPARATOR
Intervention: Education-only control
Number of subjects: 11716
Study 7956212 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms EE OC
Number of subjects: 238
Study 7956212 — intervention group
Group type: COMPARATOR
Intervention: IUD
Number of subjects: 238
Study 7956212 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant implants
Number of subjects: 238
Study 3328343 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (0.5 g/m2)
Number of subjects: 389
Study 3328343 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated nets
Number of subjects: 389
Study 31903866 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise
Number of subjects: 10
Study 31903866 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise
Number of subjects: 10
Study 31903866 — intervention group
Group type: COMPARATOR
Intervention: High-intensity exercise
Number of subjects: 10
Study 31903866 — intervention group
Group type: EXPERIMENTAL
Intervention: All intensity conditions
Number of subjects: 10
Study 29722276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab 225 mg
Number of subjects: 0
Study 29722276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab 675 mg
Number of subjects: 0
Study 29722276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29722276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab 675/225 mg
Number of subjects: 0
Study 29722276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab 900 mg
Number of subjects: 0
Study 28380009 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified biscuits
Number of subjects: 351
Study 28380009 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 351
Study 25644747 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia only group
Number of subjects: 211
Study 25644747 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid insomnia and obstructive sleep apnea group
Number of subjects: 211
Study 25644747 — intervention group
Group type: COMPARATOR
Intervention: Groups with sleep disorders (insomnia only, obstructive sleep apnea only, comorbid)
Number of subjects: 211
Study 23531491 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Natural
Number of subjects: 15
Study 23531491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mostly Natural
Number of subjects: 15
Study 23531491 — intervention group
Group type: COMPARATOR
Intervention: Mostly Built
Number of subjects: 15
Study 23531491 — intervention group
Group type: COMPARATOR
Intervention: Very Built
Number of subjects: 15
Study 21062645 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity treatment (primary care provider counseling plus additional counseling by an auxiliary staff member)
Number of subjects: 261
Study 21062645 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity control treatment (primary care provider counseling only)
Number of subjects: 261
Study 19054832 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative sub-Tenon levobupivacaine
Number of subjects: 54
Study 19054832 — intervention group
Group type: COMPARATOR
Intervention: Topical anaesthetic eye-drops only
Number of subjects: 54
Study 16900645 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (GSVL)
Number of subjects: 57
Study 16900645 — intervention group
Group type: COMPARATOR
Intervention: fiberoptic bronchoscope (FOB)
Number of subjects: 57
Study 14978663 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose D-penicillamine (822 mg daily)
Number of subjects: 134
Study 14978663 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose D-penicillamine (120 mg every other day)
Number of subjects: 134
Study 14978663 — intervention group
Group type: COMPARATOR
Intervention: Active control (D-penicillamine)
Number of subjects: 134
Study 14978663 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin score
Number of subjects: 134
Study 14978663 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability index of the Health Assessment Questionnaire (HAQ-DI)
Number of subjects: 134
Study 14978663 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician global assessment
Number of subjects: 134
Study 12202467 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 7
Study 12202467 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg or more)
Number of subjects: 7
Study 12202467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9620517 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20
Study 9620517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20
Study 9620517 — intervention group
Group type: COMPARATOR
Intervention: 4-cm PEEP
Number of subjects: 20
Study 9620517 — intervention group
Group type: COMPARATOR
Intervention: 8-cm PEEP
Number of subjects: 20
Study 9620517 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane and Sevoflurane
Number of subjects: 20
Study 7977218 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential program (28-day duration)
Number of subjects: 646
Study 7977218 — intervention group
Group type: COMPARATOR
Intervention: Outpatient day treatment program (28-day duration)
Number of subjects: 646
Study 2513172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric nutrition (32 +/- 3.8 kcal/kg/d and 1.23 g/kg/d of protein)
Number of subjects: 17
Study 2513172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric nutrition (less than 50% of calories and same protein as Group 2)
Number of subjects: 17
Study 2513172 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 +/- 1.2 kcal/kg/d with no protein)
Number of subjects: 17
Study 4624222 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide excision (extended tylectomy)
Number of subjects: 370
Study 4624222 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 370
Study 31218369 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-back task (TBT) during pain
Number of subjects: 28
Study 31218369 — intervention group
Group type: COMPARATOR
Intervention: REST during pain
Number of subjects: 28
Study 28374908 — intervention group
Group type: EXPERIMENTAL
Intervention: p‐hCG levels measured 14 days after Day‐2 SET
Number of subjects: 466
Study 28374908 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of p‐hCG levels
Number of subjects: 466
Study 28374908 — intervention group
Group type: EXPERIMENTAL
Intervention: Three highest p‐hCG quartiles
Number of subjects: 466
Study 26030760 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifamily group (MFG) intervention
Number of subjects: 174
Study 24111682 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly foreseeable outcomes in bullying situations
Number of subjects: 163
Study 24111682 — intervention group
Group type: EXPERIMENTAL
Intervention: Unforeseeable outcomes in bullying situations
Number of subjects: 163
Study 24111682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying situations occurring in school
Number of subjects: 163
Study 24111682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying situations occurring online
Number of subjects: 163
Study 20416959 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component exercise intervention
Number of subjects: 0
Study 20416959 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued exercise
Number of subjects: 0
Study 20416959 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued resistance training
Number of subjects: 0
Study 20416959 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19672568 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiCor (500 mg of a dried, modified Saccharomyces cerevisiae oral fermentation product)
Number of subjects: 96
Study 19672568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 17400821 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile
Number of subjects: 0
Study 15125911 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural threat condition (greatest vs. least)
Number of subjects: 32
Study 15125911 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (OA) under postural threat
Number of subjects: 32
Study 15125911 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults (YA) under postural threat
Number of subjects: 32
Study 11528359 — intervention group
Group type: COMPARATOR
Intervention: Red clover extracts
Number of subjects: 5
Study 9779695 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 32
Study 9779695 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release morphine
Number of subjects: 32
Study 7803885 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine2-receptor antagonists
Number of subjects: 0
Study 7803885 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 0
Study 7803885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0
Study 7803885 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic agents (general)
Number of subjects: 0
Study 2928038 — intervention group
Group type: EXPERIMENTAL
Intervention: Opaque, sealed bottle containing sugar
Number of subjects: 50
Study 2928038 — intervention group
Group type: COMPARATOR
Intervention: Control bottle containing sand
Number of subjects: 50
Study 4311189 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot tetracosactrin
Number of subjects: 12
Study 4311189 — intervention group
Group type: COMPARATOR
Intervention: Corticotrophin gel
Number of subjects: 12
Study 31196231 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0
Study 31196231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28407811 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 15000
Study 28407811 — intervention group
Group type: COMPARATOR
Intervention: Balanced crystalloids (Lactated Ringer's or Plasma‐Lyte A©)
Number of subjects: 15000
Study 25837207 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Number of subjects: 24
Study 25837207 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 24
Study 23453871 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation
Number of subjects: 881
Study 21205385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (FS)
Number of subjects: 258
Study 21205385 — intervention group
Group type: COMPARATOR
Intervention: Ferric pyrophosphate (FPP)
Number of subjects: 258
Study 18056791 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA+CHO
Number of subjects: 16
Study 18056791 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 16442045 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser lipolysis
Number of subjects: 30
Study 16442045 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser lipolysis followed by biweekly treatments with the Tri-active system
Number of subjects: 30
Study 16442045 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 15896584 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 120
Study 15896584 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 120
Study 15896584 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 16 mg
Number of subjects: 120
Study 15896584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12538199 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (3.5-5 mg) plus ketamine (20/30 mg)
Number of subjects: 104
Study 12538199 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (3.5-5 mg)
Number of subjects: 104
Study 10396749 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A botulinum toxin (AGN 191622) - 10 units (group H)
Number of subjects: 41
Study 10396749 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A botulinum toxin (AGN 191622) - 5 units (group M)
Number of subjects: 41
Study 10396749 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A botulinum toxin (AGN 191622) - 1 unit (group L)
Number of subjects: 41
Study 7564134 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon with 20 seconds removal time
Number of subjects: 40
Study 7564134 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon with 40 seconds removal time
Number of subjects: 40
Study 7564134 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon GV with 20 seconds removal time
Number of subjects: 40
Study 7564134 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon GV with 40 seconds removal time
Number of subjects: 40
Study 7564134 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 40
Study 2405653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) cephalothin (250 mg/L) and tobramycin (8 mg/L)
Number of subjects: 39
Study 2405653 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin (400 mg loading followed by 300 mg daily)
Number of subjects: 39
Study 2405653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ofloxacin (400 mg followed by 300 mg daily) and rifampicin (300 mg daily)
Number of subjects: 39
Study 6252744 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 33-824 (0.5 mg im)
Number of subjects: 20
Study 6252744 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (4 mg iv)
Number of subjects: 20
Study 6252744 — intervention group
Group type: COMPARATOR
Intervention: Lysine vasopressin (5 IU im)
Number of subjects: 20
Study 6252744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31227978 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule debridement during CIED replacement
Number of subjects: 773
Study 31227978 — intervention group
Group type: COMPARATOR
Intervention: No capsule debridement during CIED replacement
Number of subjects: 773
Study 29353712 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led collaborative care intervention
Number of subjects: 325
Study 29353712 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 325
Study 26898519 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual planning
Number of subjects: 50
Study 26898519 — intervention group
Group type: COMPARATOR
Intervention: Conventional planning
Number of subjects: 50
Study 26898519 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 24117002 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplementation (150 μg of potassium iodide daily) - Group A
Number of subjects: 365
Study 24117002 — intervention group
Group type: COMPARATOR
Intervention: No iodine supplementation - Group B
Number of subjects: 365
Study 22431865 — intervention group
Group type: EXPERIMENTAL
Intervention: PG guidance using either PG-1 or PG-2 algorithms
Number of subjects: 2370
Study 22431865 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-2 algorithm
Number of subjects: 2370
Study 22431865 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2370
Study 22431865 — intervention group
Group type: EXPERIMENTAL
Intervention: PG guidance
Number of subjects: 2370
Study 21091414 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy interventions including daily supervised, progressive exercises until discharge and a postoperative exercise booklet on discharge
Number of subjects: 76
Study 19066757 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/valsartan 300/320 mg
Number of subjects: 581
Study 19066757 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren 300 mg
Number of subjects: 581
Study 19066757 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 581
Study 19066757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581
Study 17283532 — intervention group
Group type: EXPERIMENTAL
Intervention: KAI1 positive group
Number of subjects: 110
Study 17283532 — intervention group
Group type: EXPERIMENTAL
Intervention: nm23 positive group
Number of subjects: 110
Study 17283532 — intervention group
Group type: EXPERIMENTAL
Intervention: ETS-1 positive group
Number of subjects: 110
Study 17283532 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF positive group
Number of subjects: 110
Study 17283532 — intervention group
Group type: EXPERIMENTAL
Intervention: Common expression of KAI1 and nm23
Number of subjects: 110
Study 17283532 — intervention group
Group type: EXPERIMENTAL
Intervention: Common expression of ETS-1 and VEGF
Number of subjects: 110
Study 17283532 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressions of KAI1, nm23, ETS-1, and VEGF proteins
Number of subjects: 110
Study 14560825 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cannulated cancellous lag screws
Number of subjects: 10
Study 14560825 — intervention group
Group type: COMPARATOR
Intervention: 2 cannulated cancellous lag screws
Number of subjects: 10
Study 10793604 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm air sensation at 40 +/- 0.2 degrees C
Number of subjects: 30
Study 10793604 — intervention group
Group type: COMPARATOR
Intervention: Cold sensation from ethyl chloride spray
Number of subjects: 30
Study 8619185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacron patch angioplasty
Number of subjects: 190
Study 8619185 — intervention group
Group type: COMPARATOR
Intervention: Vein patch angioplasty
Number of subjects: 190
Study 1428035 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 129
Study 1428035 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg once daily
Number of subjects: 129
Study 6399250 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs
Number of subjects: 6
Study 6399250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31014267 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of moderate-intensity treadmill walking
Number of subjects: 27
Study 31014267 — intervention group
Group type: COMPARATOR
Intervention: 30 min of seated rest
Number of subjects: 27
Study 31014267 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) split (≥45 min average daily MVPA)
Number of subjects: 27
Study 29756474 — intervention group
Group type: EXPERIMENTAL
Intervention: Henna applied with 15 cm extent on the patients' sacrum along with standard prevention cares for decubitus ulcers.
Number of subjects: 80
Study 29756474 — intervention group
Group type: COMPARATOR
Intervention: Standard prevention cares for decubitus ulcers (Control group).
Number of subjects: 80
Study 27987595 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily thoracic radiotherapy (TRT) (45 Gy/30 fractions)
Number of subjects: 157
Study 27987595 — intervention group
Group type: COMPARATOR
Intervention: Once-daily thoracic radiotherapy (TRT) (42 Gy/15 fractions)
Number of subjects: 157
Study 27987595 — intervention group
Group type: EXPERIMENTAL
Intervention: First chemotherapy-course
Number of subjects: 157
Study 27987595 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in SOD
Number of subjects: 157
Study 24745024 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced feedback in virtual environment (RFVE)
Number of subjects: 44
Study 24745024 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation (TR)
Number of subjects: 44
Study 22266545 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 14
Study 22266545 — intervention group
Group type: COMPARATOR
Intervention: Quiet sitting
Number of subjects: 14
Study 20522615 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (LD) pantoprazole (0.3 mg/kg)
Number of subjects: 60
Study 20522615 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose (MD) pantoprazole (0.6 mg/kg)
Number of subjects: 60
Study 20522615 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) pantoprazole (1.2 mg/kg)
Number of subjects: 60
Study 20522615 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose (MD) pantoprazole (0.6 mg/kg) for EE
Number of subjects: 60
Study 20522615 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) pantoprazole (1.2 mg/kg) for EE
Number of subjects: 60
Study 18847151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized steroid fluticasone (Flixotide Nebules)
Number of subjects: 73
Study 18847151 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 73